Compositions comprising relaxin and methods of use thereof
The present invention provides methods for treating a stiffened joint in a subject that comprise administering relaxin, e.g., a PEGylated relaxin-2, to the subject. The relaxin may be administered intra-articularly as a sustained release formulation. The present invention also provides sustained release formulations in the form of a hydrogel for administering polypeptides that are covalently attached to a polymer, e.g., PEG.
1. A method for treating a stiffened joint resulting from fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of relaxin-2 or a mutant thereof, such that the stiffened joint resulting from fibrosis in the subject is treated; wherein the relaxin-2 or a mutant thereof does not include relaxin attached to an immunoglobulin or a fragment of an immunoglobulin; wherein the relaxin-2 or a mutant thereof comprises an amino acid sequence having at least 95% sequence identity with any of SEQ ID NOS: 1-3; and wherein the relaxin-2 or a mutant thereof treats the stiffened joint by treating fibrosis; and wherein the stiffened joint resulting from fibrosis comprises adhesive capsulitis.
2. The method of claim 1 , wherein the relaxin-2 or a mutant thereof comprises an amino acid sequence having at least 99% sequence identity with any of SEQ ID NOS: 1-3.
3. The method of claim 1 , wherein the stiffened joint resulting from fibrosis is selected from the group consisting of a shoulder joint, an elbow joint, a wrist joint, a finger joint, a hip joint, a knee joint, and an ankle joint.
4. The method of claim 1 , wherein the relaxin-2 or a mutant thereof is administered as a part of a sustained-release formulation.
5. The method of claim 4 , wherein the sustained-release formulation is a hydrogel further comprising at least one polymer.
6. The method of claim 5 , wherein the at least one polymer is selected from the group consisting of polyethylene glycol (PEG), alginate, agarose, poly(ethylene glycol dimethacrylate), polylactic acid, polyglycolic acid, PLGA, gelatin, collagen, agarose, pectin, poly(lysine), polyhydroxybutyrate, poly-epsilon-caprolactone, polyphosphazines, poly(vinyl alcohol), poly(alkylene oxide), poly(ethylene oxide), poly(allylamine), poly(acrylate), poly(4-aminomethylstyrene), pluronic polyol, polyoxamer, poly(uronic acid), poly(anhydride) and poly(vinylpyrrolidone).
7. The method of claim 6 , wherein the polymer is PEG.
8. The method of claim 7 , wherein the PEG is covalently attached to the relaxin-2 or a mutant thereof.
9. The method of claim 8 , wherein the hydrogel is formed in situ following mixing of the relaxin-2 or a mutant thereof and a cross-linker, wherein the cross-linker comprises:
a polypeptide reactive moiety covalently attached to PEG and a linker as illustrated by the following schematic:
wherein:
the polypeptide reactive moiety comprises at least one amine- or a thiol-reactive group; and
the linker comprises a moiety cleavable via a chemical or an enzymatic reaction.
10. The method of claim 9 , wherein the cross-linker has the following structural formula:
wherein:
n is 20-500;
m is any number from 1 to 10; and
p is any number from 1 to 6.
11. The method of claim 8 , wherein the hydrogel additionally comprises a filler polypeptide covalently attached to the PEG.
12. The method of claim 1 , wherein the relaxin-2 or a mutant thereof is administered by an intraarticular injection.
13. A method for treating a stiffened joint resulting from fibrosis in a subject in need thereof, the method comprising administering to the subject an effective amount of relaxin-2 or a mutant thereof, such that the stiffened joint resulting from fibrosis in the subject is treated wherein the relaxin-2 or a mutant thereof does not include relaxin attached to an immunoglobulin or a fragment of an immunoglobulin; wherein the relaxin-2 or a mutant thereof comprises an amino acid sequence having at least 95% sequence identity with any of SEQ ID NOS: 1-3; and wherein the relaxin-2 or a mutant thereof treats the stiffened joint by treating fibrosis; and wherein the stiffened joint resulting from fibrosis comprises fibrosis involving capsule of the joint.
14. The method of claim 13 , wherein the relaxin-2 or a mutant thereof comprises an amino acid sequence having at least 99% sequence identity with any of SEQ ID NOS: 1-3.
15. The method of claim 13 , wherein the stiffened joint resulting from fibrosis is selected from the group consisting of a shoulder joint, an elbow joint, a wrist joint, a finger joint, a hip joint, a knee joint, and an ankle joint.
16. The method of claim 13 , wherein the relaxin-2 or a mutant thereof is administered as a part of a sustained-release formulation.
17. The method of claim 16 , wherein the sustained-release formulation is a hydrogel further comprising at least one polymer.
18. The method of claim 17 , wherein the at least one polymer is selected from the group consisting of polyethylene glycol (PEG), alginate, agarose, poly(ethylene glycol dimethacrylate), polylactic acid, polyglycolic acid, PLGA, gelatin, collagen, agarose, pectin, poly(lysine), polyhydroxybutyrate, poly-epsilon-caprolactone, polyphosphazines, poly(vinyl alcohol), poly(alkylene oxide), poly(ethylene oxide), poly(allylamine), poly(acrylate), poly(4-aminomethylstyrene), pluronic polyol, polyoxamer, poly(uronic acid), poly(anhydride) and poly(vinylpyrrolidone).
19. The method of claim 18 , wherein the polymer is PEG.
20. The method of claim 19 , wherein the PEG is covalently attached to the relaxin-2 or a mutant thereof.
21. The method of claim 20 , wherein the hydrogel is formed in situ following mixing of the relaxin-2 or a mutant thereof and a cross-linker, wherein the cross-linker comprises:
a polypeptide reactive moiety covalently attached to PEG and a linker as illustrated by the following schematic:
wherein:
the polypeptide reactive moiety comprises at least one amine- or a thiol-reactive group; and
the linker comprises a moiety cleavable via a chemical or an enzymatic reaction.
22. The method of claim 21 , wherein the cross-linker has the following structural formula:
wherein:
n is 20-500;
m is any number from 1 to 10; and
p is any number from 1 to 6.
23. The method of claim 20 , wherein the hydrogel additionally comprises a filler polypeptide covalently attached to the PEG.
24. The method of claim 13 , wherein the relaxin-2 or a mutant thereof is administered by an intraarticular injection.